Article
Breakingviews - Roche's $7 bln deal is pricey and partial cure
Rating:
0.0
Views:
41
Likes:
1
Library:
1
Roche has taken a small step towards curing its drug pipeline problem. The Swiss pharmaceutical giant on Monday announced it was paying $7.1 billion to Roivant and Pfizer for the U.S. and Japanese rights to develop a potential treatment for inflammatory bowel disease. New Chief Executive Thomas Schinecker will need to aim much bigger to successfully refresh the $215 billion group's portfolio.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value